Despite variability in populations, substrate drugs, and doses, our findings demonstrate that carbamazepine is an inducer at 300 mg/day, and that ASMs can rank differently as CYP2C9 versus P-gp inducers. Therefore, the safety of ASM polytherapy cannot be extrapolated from one pathway to another for treatment selection, for example, for post-stroke epilepsy.
Building similarity graph...
Analyzing shared references across papers
Loading...
Hagar Cohen
Nahawand Bahash
Tomer Ben‐Shushan
Epileptic Disorders
Hebrew University of Jerusalem
National Library of Israel
Building similarity graph...
Analyzing shared references across papers
Loading...
Cohen et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d8967d6c1944d70ce07f5d — DOI: https://doi.org/10.1002/epd2.70232